Revvity IncNYSE:RVTY
- LAST PRICE122.8900
- TODAY'S CHANGE (%)-3.5900 (-2.8384%)
- Bid / Lots120.6500/ 1
- Ask / Lots125.3600/ 1
- Open / Previous Close124.9300 / 126.4800
- Day Range
- 52 Week Range
- Volume1,349,703
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Aug 27, 2024
DJ Revvity Initiated at Equal-Weight by Wells Fargo, from 5:59PM ET on Tuesday Aug 27, 2024 by Dow Jones
5:59PM ET on Tuesday Aug 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Revvity Inc | 15.2B | 76.9x | -7.39% |
Waters Corp | 20.0B | 33.5x | +7.16% |
Bruker Corp | 10.2B | 28.1x | +20.48% |
Hologic Inc | 18.9B | 27.8x | --- |
QuidelOrtho Corp | 3.1B | -1.6x | --- |
Evolent Health Inc | 3.6B | -33.1x | --- |
Company Information
Revvity, Inc. is a provider of health science solutions, technologies, and services, which delivers workflows from discovery to development, and diagnosis to cure. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The Life Sciences Segment applications include MicroBeta, The MuviCyte live-cell imaging system, The Signals Image Artist, The VICTOR Nivo multimode plate reader benchtop system, The EnSight multimode plate reader benchtop system, BioLegend LEGENDplex bead-based reagents, and The Quantum GX2 system. Its Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. It offers instruments, reagents, assay platforms and software to hospitals, and medical labs. It is focused on reproductive health, immunodiagnostics, and emerging market diagnostics.
Contact Information
- Headquarters
- 940 Winter StreetWALTHAM, MA, United States 02451
- Phone
- 781-663-5791
- Fax
- ---
Executives
- Independent Non-Executive Chairman of the Board
- Alexandros Michas
- President, Chief Executive Officer, Director
- Prahlad Singh
- Chief Financial Officer, Senior Vice President
- Maxwell Krakowiak
- Senior Vice President - Administration, General Counsel, Secretary
- Joel Goldberg
- Senior Vice President - Strategy and Business Development
- Daniel Tereau
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.2B |
|---|---|
Revenue (TTM) | $2.7B |
Shares Outstanding | 123.3M |
Dividend Yield | 0.23% |
Annual Dividend Rate | 0.2800 USD |
Ex-Dividend Date | 10-18-24 |
Pay Date | 11-08-24 |
Beta | 1.05 |
EPS | $1.60 |
Book Value | $63.79 |
P/E Ratio | 76.9x |
Price/Sales (TTM) | 5.6 |
Price/Cash Flow (TTM) | 24.2x |
Operating Margin | 10.20% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
